Research & Development
Patients & Caregivers
Investors & News
Regulation Kits
Careers

ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate — deforolimus, a novel mTOR inhibitor — has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.

Controlling Cancer

Controlling cell signaling to develop new targeted cancer therapies.
MORE >

Moving Rapidly

Deforolimus has FDA Fast Track designation and orphan drug status; The SUCCEED trial is being conducted under Special Protocol Assessment.
MORE >

Growing Our Team

ARIAD is positioned to make a difference in cancer care.
MORE >

Email Page  Print Page
©2008 ARIAD Pharmaceuticals, Inc.
Terms and Conditions   Privacy Policy   Safe Harbor   Map & Directions